CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to DSKYF

Ifinatamab deruxtecan

Phase 3
Daiichi Sankyo (DSKYF)

Phase 3

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Sep '26
DSKYFPhase 2
✗Negative

Ifinatamab deruxtecan Phase 2 Est. Readout

Ifinatamab deruxtecan
Sep 2026~
CT.gov
Competitive Landscape

0 competitors in Esophageal Squamous Cell Carcinoma

View Full Landscape
Drug Information

Target Indication

Esophageal Squamous Cell Carcinoma

Clinical Trial

NCT06644781

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.